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Abstract 
Background: HIV-1 hijacks host cell machinery to ensure successful replication, including cytoskeletal components 
for intracellular trafficking, nucleoproteins for pre-integration complex import, and the ESCRT pathway for assembly 
and budding. It is widely appreciated that cellular post-translational modifications (PTMs) regulate protein activity 
within cells; however, little is known about how PTMs influence HIV replication. Previously, we reported that blocking 
deacetylation of tubulin using histone deacetylase inhibitors promoted the kinetics and efficiency of early post-
entry viral events. To uncover additional PTMs that modulate entry and early post-entry stages in HIV infection, we 
employed a flow cytometric approach to assess a panel of small molecule inhibitors on viral fusion and LTR promoter-
driven gene expression.
Results: While viral fusion was not significantly affected, early post-entry viral events were modulated by drugs 
targeting multiple processes including histone deacetylation, methylation, and bromodomain inhibition. Most 
notably, we observed that inhibitors of the Rho GTPase family of cytoskeletal regulators—including RhoA, Cdc42, and 
Rho-associated kinase signaling pathways—significantly reduced viral infection. Using phosphoproteomics and a 
biochemical GTPase activation assay, we found that virion-induced signaling via CD4 and CCR5 activated Rho family 
GTPases including Rac1 and Cdc42 and led to widespread modification of GTPase signaling-associated factors.
Conclusions: Together, these data demonstrate that HIV signaling activates members of the Rho GTPase family of 
cytoskeletal regulators that are required for optimal HIV infection of primary CD4+ T cells.
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Background
HIV-1, like other viruses, relies on host cellular machin-
ery to successfully complete replication. The proteins 
co-opted by HIV, collectively known as host depend-
ency factors, have been investigated using a variety 
of approaches including functional genomic screens 
with siRNAs [1–3]. These studies have revealed that 
host dependency factors fall into a variety of pathways 
including cytoskeletal and transport proteins, compo-
nents of nuclear pore complexes, LEDGF/p75, mRNA 
transcription, RNA export and translation machin-
ery, ER/Golgi trafficking, and members of the ESCRT 
machinery [1, 2, 4]. Although these high-throughput 
screens have been informative in identifying novel host 
dependency factors, they rely on changes in HIV replica-
tion due to altered protein expression levels. However, 
it is well-recognized that protein function is controlled 
not only by expression levels, but also by a variety of 
post-translational modifications (PTMs) that may be 
overlooked in conventional knockdown screening 
approaches. For example, the histone acetyltransferases 
p300/CBP were not identified as host dependency factors 
in siRNA screens despite known interactions with Tat 
and integrase and reports of reduced HIV replication in 
the presence of specific p300 inhibitors [5–9].
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In the context of HIV-1, PTMs play important roles in 
several steps of viral replication. Acetylation and meth-
ylation of histone residues on viral-associated nucle-
osomes impact chromatin structure and accessibility of 
the viral promoter to cellular transcriptional machin-
ery [10, 11]. For instance, histone deacetylase (HDAC) 
inhibitors promote viral reactivation from latency both 
in vitro and in vivo and are being investigated as potential 
latency reversing agents in strategies to eliminate latent 
viral reservoirs [12–15]. Recently, we reported an unan-
ticipated effect of HDAC inhibitors on HIV infection 
that was independent of its effects on nuclear histones: 
pre-treatment of primary CD4+ T cells with drugs that 
inhibited the cytoplasmic HDAC6 enhanced the kinetics 
and efficiency of reverse transcription, nuclear import, 
and integration and led to a significant increase in sus-
ceptibility to HIV infection [16]. The mechanism of this 
phenomenon, informed also by studies from Naghavi and 
colleagues [17–19], appears to be related to the formation 
of stable acetylated microtubule networks induced by 
HIV—and enhanced by blocking tubulin deacetylation by 
HDAC6. These networks subsequently serve as conduits 
for efficient migration of viruses from the cytoplasm to 
the nucleus [18–20].
Additionally, phosphorylation has also been implicated 
in regulating susceptibility of cells to HIV. A compre-
hensive phosphoproteomic analysis of signaling events 
induced by HIV binding to cell surface receptors via CD4 
and CXCR4 revealed more than 200 phosphorylation 
sites that were altered following HIV exposure, several 
of which were confirmed to directly impact viral replica-
tion [21]. More recently, phosphorylation of the CDK9 
T-loop (Thr-175) of the positive transcription elongation 
factor, P-TEFb, and of HEXIM1 have also been impli-
cated in enhancing proviral HIV gene expression [22, 23]. 
Importantly, all of these post-translational modifications 
impacting HIV infection would be difficult or impossible 
to detect using conventional knockdown approaches.
In this study, we sought to investigate the role of PTMs 
on the efficiency of HIV-1 fusion and infection. To 
achieve this, we selected a commercially available panel 
of small molecule inhibitors tailored to enzymes involved 
in epigenetic and PTM pathways and analyzed them 
using a combination reporter virus system that measures 
both viral fusion and LTR-driven EGFP expression, which 
requires not only fusion but also post-entry steps includ-
ing uncoating, reverse transcription, nuclear import, 
integration, Tat-dependent transcription and Rev-
dependent mRNA export, and translation to occur suc-
cessfully [24]. While the majority of compounds had no 
effect at the level of fusion, 39 compounds yielded greater 
than 0.5 log2 fold change in viral infection as measured by 
LTR-driven EGFP expression. Most notably, all histone 
deacetylase inhibitors tested increased EGFP expression, 
in agreement with our previous findings that pan-HDAC 
inhibitors vorinostat, panibinostat, romidepsin, and the 
HDAC6-specific inhibitor tubacin enhanced viral infec-
tion [16]. Conversely, inhibitors of histone and DNA 
methylation predominated the list of compounds that 
reduced HIV infection. Interestingly, the small molecule 
CCG-100602, reported to inhibit Rho GTPase signaling 
[25], was identified in our screen as a negative regulator 
of HIV. Based on this observation, we tested additional 
inhibitors of the Rho family GTPases Cdc42 and the Rho-
associated protein kinase (ROCK) and observed similar 
reductions in HIV infection. Finally, using phosphopro-
teomic and biochemical analysis of signaling pathways 
altered by HIV binding to CD4 and CCR5, we observed 
that HIV signaling activates the small GTPases Rac1 
and Cdc42 and induces a dramatic restructuring in the 
phosphorylation cascades of Rho family GTPases and 
associated proteins, suggesting that the activity of these 
pathways is modulated directly by the virus. Together, 
these data indicate that HIV signaling via its receptors at 
the time of attachment activates Rho family GTPases and 
that RhoA, Cdc42, and ROCK are host dependency fac-
tors for optimal HIV infection of primary CD4+ T cells.
Methods
Small molecule inhibitors
The 96-well “epigenetic screening library” was acquired 
from Cayman Chemical and stored at −20 °C as 10 mM 
stocks in DMSO (Batch #0449323). Small molecule inhib-
itors were serially diluted in RPMI 1640/10% FBS/1% 
PenStrep for a final effective range of 10  nM–10  μM 
immediately prior to experimental setup. Multiple 
freeze-thaw cycles were prevented to exclude potential 
variations in drug potency.
Infection experiments
1 × 106 unstimulated primary CD4+ T cells were plated 
per well in a 96-well format and incubated for 4 h at 37 °C 
with media alone or media supplemented with 10  nM, 
100  nM, 1  μM, or 10  μM of indicated small molecule 
inhibitor. Parallel plates were prepared for analysis of 
viral fusion and LTR-driven EGFP expression as previ-
ously described [24]. Following incubation with small 
molecule inhibitors, cells were infected with HIV-1 
reporter virus strain NL4-3-deltaE-EGFP (obtained 
through the NIH AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: pNL4-3-delta-
E-EGFP (Cat #11100) from Drs. Haili Zhang, Yan Zhou, 
and Robert Siliciano) bearing CXCR4-tropic envelope 
JOTO.TA1.2247 [26] and a β-lactamase-Vpr fusion pro-
tein [27, 28]. Plates were spinoculated for 2 h at 1200 rpm 
and 25 °C. Following centrifugation, cells were incubated 
Page 3 of 13Lucera et al. Retrovirology  (2017) 14:4 
for 1 h at 37 °C. Cells for viral fusion analysis were treated 
with CCF2-AM, washed, and incubated overnight at 
room temperature in the presence of probenecid. For 
EGFP expression, cells were incubated at 37 °C for a total 
of 72 h prior to staining and processing.
Flow cytometry
Cells were washed once with PBS containing 1% BSA 
and incubated with live/dead near-IR fixable viability dye 
(Invitrogen), CD3 Brilliant Violet 650 (BioLegend), and 
CD4 Allophycocyanin (eBioscience) at 4  °C for 30  min. 
Cells were washed in PBS/BSA and fixed in PBS/BSA 
containing 1% paraformaldehyde prior to data acquisi-
tion. All samples were analyzed using a BD Fortessa (BD 
Biosciences) cell analyzer equipped with a High Through-
put Sampler option. A minimum of 50,000 events were 
collected per sample at a flow rate of 2.5 μL/s with 50 μL 
mixing and 3 × 200 μL washes. All experimental condi-
tions were performed in triplicate. FlowJo version 9.7.6 
(TreeStar, Inc) was used for analysis. For downstream 
validation of significant hits, the above experiments 
above were repeated in triplicate on a minimum of 3 
healthy donor CD4+ T cell populations.
β‑lactamase‑mediated cleavage of CCF2 in HEK293T cells
Human embryonic kidney 293T/17 cells were seeded in 
10 cm2 dishes at a density of 3 × 106 cells per dish. Cells 
were transfected with 7.5  μg β-lactamase-Vpr plasmid 
using previously established calcium phosphate methods 
and fresh media was added 6 h post transfection. At 48 h 
post transfection, cells were incubated with media alone 
or media containing 10 μM chaetocin for 4 h. Cells were 
subsequently treated with CCF2-AM for 2  h at room 
temperature, washed, and incubated overnight in CO2-
independent media containing probenecid. The following 
day, cells were trypsinized, stained with live/dead near-
IR viability dye and analyzed for evidence of substrate 
cleavage.
Phosphoproteomic analysis of HIV‑exposed CD4+ T cells
Memory CD4+ T cells were purified by negative selec-
tion from a leukapheresis pack using custom RosetteSep 
kits (STEMCELL Technologies). Briefly, equal popula-
tions of 150  ×  106 cells were exposed to 20  μg/ml p24 
equivalent AT2-inactivated HIV-1 THRO or protein 
equivalent concentrations of non-viral microvesicles 
as control. HIV-1 THRO is a transmitted/founder virus 
isolated from a subject with early HIV infection that was 
found to be CCR5-tropic as evidenced by inhibition by 
TAK779 but not AMD3100 on TZM-bl cells and by its 
inability to replicate in PBMCs from a patient with the 
delta32-ccr5 mutation [29]. The AT2-inactivated viruses 
were derived from a cell clone of THRO (THRO CL.29) 
that was produced by co-culturing HEK293T cells 
transfected with the patient-derived THRO with A66-
R5 cells and was identical in amino acid to the parental 
virus with the exception of Vif T68I, Vpu A8V, and Env 
R298K mutations. THRO CL.29 productively infected 
A66 cells expressing CCR5 but did not infect A66 cells 
that expressed CXCR4 (Julian Bess, personal commu-
nication). Following stimulation for 1, 15, and 60-min 
periods, cells were incubated with cold PBS containing 
protease and phosphatase inhibitors. Cells were washed, 
lysed with 2% SDS, and digested enzymatically with 
trypsin. Phosphopeptides were enriched with titanium 
dioxide and purified by long gradient UPLC. Enriched 
samples were analyzed by LC-MS/MS and analyzed with 
Ingenuity Pathway Analysis (Ingenuity).
Small GTPase activation assay
Purified CD4+ T cells were resuspended at 5 ×  106/ml 
in RPMI/10% FBS and rested overnight. Cells were then 
pelleted at 800×g for 5 min followed by resuspension in 
RPMI without FBS, rested at 37 °C for 1 h, and exposed 
to AT2-inactivated THRO or protein equivalent con-
centrations of non-viral microvesicles as detailed above. 
After a 1  min incubation, ice-cold PBS containing pro-
tease and phosphatase inhibitors was immediately added, 
cells were pelleted at 800×g for 5 min and resuspended 
in ice-cold cell lysis buffer. Cells were transferred to a 
new tube, clarified by centriguation at 10,000×g for 1 
min at 4  °C and snap-frozen in liquid nitrogen. Follow-
ing determination of protein concentration, cell lysates 
were thawed, normalized for protein concentration with 
lysis buffer, and analyzed using a RhoA, Rac1, and Cdc42 
G-LISA activation assay (Cytoskeleton, Inc.) according to 
the manufacturers instructions.
Statistics
Data presented as mean values with standard error of 
the mean unless stated otherwise. All differences with a 
p value of <0.05 were considered statistically significant, 
correcting for multiple comparisons when appropriate. 
Statistical analyses were performed using student t-tests 
within GraphPad Prism v7.0.
Results
Viral fusion is not affected by compounds in an epigenetic /  
post‑translational modification screening library
The importance of post-translational modifications 
(PTMs) on HIV replication has been extensively studied 
in the context of HIV-1 reactivation from latency, where 
PTMs regulate the accessibility of host transcription fac-
tors and the RNA polymerase machinery to the HIV-1 
LTR promoter. Most significantly, the histone deacetylase 
(HDAC) family of enzymes has become a leading target 
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of pharmacological inhibition in efforts to eliminate viral 
reservoirs from infected individuals by promoting reac-
tivation of HIV from latency [13]. Recently, we reported 
this class of drugs has previously unknown effects on 
early post-entry events in HIV infection, increasing the 
kinetics and efficiency of reverse transcription and inte-
gration [16]. Surprisingly, this enhancement was not due 
to alterations of histone acetylation but rather to inhibi-
tion of the cytoplasmic HDAC6, which regulates tubulin 
acetylation and microtubule stability [16–19]. To probe 
for additional epigenetic or post-translational modifica-
tions regulating HIV-1 replication, we employed the use 
of a small molecule inhibitor epigenetic / post-transla-
tional modification (PTM) screening library (Additional 
file 1: Table 1) with our combination reporter virus sys-
tem that measures both viral fusion and LTR-driven 
EGFP expression [24]. Viruses bearing a CXCR4-tropic 
HIV Env were chosen based on the expression of this 
receptor on a greater percentage of primary CD4+ T 
cells when compared to the CCR5 co-receptor [30–33]. 
Compounds within this library have previously been 
reported to have multiple targets including—but not 
limited to—histone acetylation and methylation, kinase 
signaling, and bromodomain and extraterminal domain 
(BET) protein family members. All compounds screened 
were prepared in equal experimental conditions and were 
analyzed across a 3-log concentration to minimize vari-
ability of half-maximal inhibitory concentrations (IC50) 
between compounds. For the initial screen, compounds 
exhibiting greater than ±0.5 log2 fold change (>141.5 
or <70.5%) compared to the untreated control in either 
fusion or infection were flagged as a hit.
Our results suggested the majority of compounds 
tested yielded little to no effect on the level viral fusion 
when compared to untreated control (Fig.  1). Initially, 
incubation of primary T cells with the small molecular 
inhibitors chaetocin and 2,4-DPD suggested an inhibi-
tory effect on viral fusion at high concentrations (Fig. 1). 
Chaetocin is a fungal metabolite that non-specifically 
inhibits histone lysine methyltransferases and therefore 
an effect at the level of viral fusion was unanticipated. 
However, given that chaetocin contains nitrogen-carbon 
bonding reminiscent of the fluorescent CCF2-AM dye 
used in the viral fusion assay, we hypothesized that chae-
tocin incubation might act as an inhibitor for β-lactamase 
mediated cleavage of CCF2-AM substrate. To test this, 
we transfected chaetocin-treated 293T cells with a plas-
mid encoding for the β-lactamase-Vpr fusion protein 
and quantified cleavage of CCF2-AM substrate. Incuba-
tion with 10  μM chaetocin resulted in a 40% reduction 
in cleavage of CCF2-AM without affecting cell viabil-
ity (96.2% of no drug control), suggesting this drug acts 
not by inhibiting viral fusion but rather by disrupting 
β-lactamase-mediated cleavage of the CCF2 dye in the 
assay (data not shown). 2,4-DPD did not inhibit viral 
fusion in additional experiments (data not shown).
HDAC, bromodomain, and prolyl hydroxylase inhibitors 
enhance HIV infection
Examination of viral fusion indicated that treatment with 
small molecule epigenetic/PTM drugs did not alter HIV 
entry into CD4+ T cells. Conversely, analyses of LTR-
driven EGFP expression revealed dramatic effects with 
compounds significant increasing cellular susceptibil-
ity to HIV-1 infection (Fig. 2a). In support of our previ-
ous report [16], 17 hits with greater than +0.5 log2 fold 
change in infection were inhibitors targeting the histone 
deacetylase class of enzymes (Fig. 2b). These results rein-
force our findings that HDAC inhibition increases sus-
ceptibility of cells to viral infection [16]. The remaining 
6 compounds increasing infection include histone lysine-
methyl binding proteins, prolyl hydroxylase inhibitors, 
and chromatin-associated bromodomain family member 
BRD2/BRD4 inhibitors (Fig. 2c). BRD2 and BRD4 are of 
significant interest since inhibitors of these proteins are 
currently being evaluated as latency reversing agents to 
eradicate latent HIV reservoirs [34–38]. It will be impor-
tant to determine whether enhanced infection observed 
here is the result of known effects, i.e. increasing viral 
transcription from the LTR promoter, or if—as with the 
HDAC inhibitors [16]—these compounds have additional 
mechanisms enhancing infection that could potentially 
complicate strategies to eradicate latent reservoirs.
Drugs targeting histone modifying enzymes inhibit HIV 
infection
The majority of non-HDAC inhibitor hits identified from 
this screen reduced infection, which could be advanta-
geous in the context of designing strategies to reduce 
transmission of HIV infection. Compounds with more 
than −0.5 log2 fold-change reduction in EGFP compared 
to baseline are shown in Fig. 3a, b. Decitabine, 2,3,5-tri-
acetyl-5-azacytidine, and 5-azacytidine are documented 
nucleoside analog reverse transcriptase inhibitors [39, 40] 
and strongly reduced infection, providing confirmation 
that our assay successfully identified known inhibitors of 
HIV. In addition, several drugs inhibiting histone dem-
ethylases, and acetyltransferases reduced HIV infection, 
including GSK-J4, C646 and garcinol. The finding that 
multiple regulators of histone modifications influence 
HIV infection increases confidence that these proteins 
and pathways play an important role in the HIV repli-
cation cycle. In addition, drugs targeting DNA methyl-
transferases, COX1, PARP1, guanylyl cyclase, and menin 
binding reduced HIV-1 infection (Fig. 3b). Three drugs—
chaetocin, tenovin-6, and UNC0638—demonstrated 
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substantial cytotoxicity 72  h after infection, suggesting 
that these agents were likely blocking HIV replication by 
killing cells. These cytotoxic effects were not apparent 
during analysis of fusion 24 h after infection.
Validation of compounds with significant effects 
on infection
To confirm effects of small molecule inhibitors found to 
increase LTR-driven EGFP in our infection analyses, we 
validated compounds on a minimum of three healthy 
donors (Fig. 4). In some instances, the range of concen-
trations tested was re-evaluated for compounds with 
conflicting reports of IC50 values (changes are noted in 
figures when applicable). Validation experiments inves-
tigating N-oxalylglycine demonstrated a slight inhibi-
tory effect—in contrast to the initial results indicating 
an increase to infection—while 2,4-PDCA, and DMOG 
did not affect infection across multiple concentra-
tions (Fig.  4). However, the small molecule inhibitors 
UNC1215, PFI-1, (+)-JQ1 consistently increased infec-
tion across all donors tested. In particular, PFI-1 was 
highly potent with concentrations as low as 10 nM yield-
ing at a twofold enhancement to viral infection (Fig. 4).
To validate small molecule inhibitors that reduced 
viral infection, we first eliminated compounds causing 
cytotoxicity or with previously documented effects on 
HIV-1 replication including nucleoside analog reverse 
transcription inhibitors [39, 40]. Our final candidate list 
included 6 compounds with effects on menin binding, 
histone modifications, DNA methyltransferases, PARP1, 
guanylyl cyclase, and COX1: MI-2, GSK-J4, lomeguatrib, 
AC014669, isoliquiritigenin, and transresveratrol. At the 
highest concentrations tested, 5/6 compounds exhibited 
significant reduction in EGFP expression with transres-
veratrol being the only compound that was not found 
to reduce EGFP expression in validation experiments 
(Fig.  4). Of all compounds inhibiting HIV infection, we 
observed the most potent effects for histone lysine dem-
ethylase inhibitor GSK-J4 at all concentrations tested.
Inhibition of Rho GTPase family members reduces HIV 
infection
An unexpected observation from our analysis was that 
treatment with small molecule CCG-100602 reduced 
LTR-driven EGFP expression in a dose-dependent fash-
ion (Fig. 5a). CCG-100602 is a specific inhibitor of RhoA 
mediated signaling [25], a pathway that regulates various 
cytoplasmic and nuclear processes including cytoskeletal 
dynamics, transcription, and cell cycle progression [41–
43]. Given our previous finding that cytoskeletal microtu-
bule networks can regulate the efficiency of HIV infection 
[16], we chose two additional inhibitors—ML-141 and 
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Fig. 1 Effect of small molecule inhibitors on viral fusion. Viral fusion was quantified using β-lactamase mediated cleavage of CCF2-AM fluorescent 
substrate. Primary CD4+ T cells were infected with CXCR4-tropic viruses following treatment to small molecule inhibition. Results are graphed as 
fold change to untreated control on log2 axis. Experimental conditions were performed in triplicate. Error bars represent SEM
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Y-27632—which target the Rho GTPase Cdc42 and Rho 
associated protein kinase (ROCK), respectively [44, 45]. In 
agreement with the RhoA findings, both inhibitors show 
pronounced reduction in EGFP+ cells suggesting that Rho 
family GTPases and downstream signaling cascades play a 
critical role facilitating HIV infection (Fig. 5b, c).
HIV has also been demonstrated to actively modu-
late cytoskeletal dynamics to promote infection, includ-
ing stimulation of acetylated microtubule networks [18] 
and rearrangements of the cortical actin barrier [46]. To 
investigate whether HIV signaling regulates Rho fam-
ily GTPases and downstream kinases, we employed an 
unbiased phosphoproteomic approach to identify cellu-
lar signaling cascades that are dysregulated in response 
to HIV-1 signaling via CD4 and CCR5. Purified memory 
CD4+ T cells were isolated from a pooled leukapher-
sis pack and exposed in parallel to non-viral microvesi-
cles or AT2-inactivated HIV-1 THRO particles. Indeed, 
Ingenuity Pathway Analysis (IPA) revealed Rho signal-
ing, including proteins involved in the RhoA, Cdc42, 
and ROCK signaling pathways, as one of the most sig-
nificantly altered cellular networks in response to HIV-1 
exposure (Fig.  6). Importantly, these signaling pathways 
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Fig. 2 Small molecular inhibitors enhancing viral infection. a Analyses of LTR-driven EGFP expression reveal that a large proportion of compounds 
present in library (49%) have greater than +0.5 log2 fold change in viral infection. b 17 compounds with greater than +0.5 log2 fold-change in EGFP 
targeted the HDAC family of enzymes, presented with percent infection compared to the no drug control (ns not significant, *p < 0.05, **p < 0.01, 
***p < 0.001) and with viability data. c Six non-HDAC compounds also demonstrated greater than +0.5 log2 fold-change in EGFP and targeted the 
L3MBTL3 methyl-lysine binging protein, cellular hydroxylases, and bromodomain proteins. For both b and c, the infection and viability data cor-
respond to the drug concentrations with the largest effect on infection with ≥70% viability compared to the no drug control. Compounds in gray 
with greater than +0.5 log2 fold change demonstrated cytotoxicity (viability ≤70%)
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and myosin, and roles for Rho family members in regu-
lating microtubule dynamics and cytoskeletal architec-
ture have been demonstrated [47–50]. To validate that 
HIV-1 signaling modulates small Rho family GTPases, we 
performed a biochemical small GTPase activation assay 
on memory CD4+ T cells from three additional healthy 
controls. Rac1 and Cdc42 were activity was signifi-
cantly increased in samples exposed to HIV as opposed 
to microvesicle controls (p  =  0.008 and p  =  0.02, 
respectively), while RhoA was not significantly altered 
(p =  0.72) (Fig. 7). Activation of Rac1 by HIV signaling 
has been previously reported [51]; however activation 
of Cdc42 by HIV-1 signaling in CD4 T cells and its role 
in promoting infection has not previously been demon-
strated. Although RhoA activation not directly observed 
with either the phosphoproteomics or biochemical 
assay, phosphorylation of the RhoA substrate ROCK was 
detected by proteomics. In addition to the proteins map-
ping to the canonical Rho GTPase signaling pathways 
in IPA, we also identified more than 20 Rho signaling-
associated proteins with significantly different phospho-
rylation patterns following exposure to inactivated HIV 
particles, including guanosine disassociation inhibitors 
(GDIs), guanosine exchange factors (GEFs), and GTPase 
activating proteins (GAPs) that regulate the activity of 
Rho family GTPases (Fig.  8a, b). Together, these data 
suggest that Rho family GTPases RhoA and Cdc42 and 
the downstream Rho-associated kinase (ROCK) are host 
dependency factors for HIV replication and that the virus 
activates Rac1 and Cdc42 and modulates the cellular 
GTPase landscape via signaling through CD4 and CCR5 
on the cell surface.  
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Fig. 3 Small molecular compounds reducing viral infection. a LTR-driven EGFP expression was reduced by more than −0.5 log2 fold change by 16 
compounds compared to no drug control (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001). b Table listing the 16 compounds reducing HIV 
infection with target proteins, percent infection, and viability data























































































































































































































































































































































Drugs enhancing HIV infection in initial screen Drugs reducing HIV infection in initial screen
Fig. 4 Validation of small molecule inhibitors affecting HIV-1 infection. Significant hits identified from preliminary analysis were validated on a mini-
mum three healthy donors. Compounds having previous effects on HIV-1 infection including nucleoside analogs were excluded from downstream 































































































Fig. 5 Inhibition of the Rho family GTPases RhoA and Cdc42 and the Rho-associated protein kinase (ROCK) reduce HIV infection. Primary CD4+ T 
cells were infected with CXCR4-tropic reporter viruses following treatment with small molecule inhibitors targeting a Rho A/C signaling, b Rho fam-
ily member Cdc42, and c Rho-kinase Rock decrease HIV LTR-driven EGFP expression. *p < 0.05, **p < 0.01, ***p < 0.001. All experimental conditions 
performed in triplicate. Error bars represent SEM
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Discussion
As an obligate intracellular pathogen, HIV-1 is reliant 
on interactions with host proteins to facilitate comple-
tion of its replication cycle. These proteins, commonly 
referred to as host dependency factors, have been uncov-
ered through a variety of experimental approaches, most 
recently high throughput knockdown approaches such as 
siRNA library screens. While knockdown and knockout 
studies are effective tools to identify novel host-patho-
gen interactions, they are not designed to investigate the 























































































































Fig. 6 Canonical Rho signaling pathways were identified in a phosphoproteomics screen of HIV-1 signaling via CD4 and CCR5. Phosphoproteomic 
analysis reveals that numerous Rho family GTPase and ROCK signaling members are dysregulated (purple) in response to HIV exposure compared 
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Fig. 7 Biochemical GTPase activation assay reveals HIV significantly activates Rac1 and Cdc42. Primary CD4+ T cells were exposed to CCR5-tropic 
HIV-1 or microvesicles for 1 min and then assessed for RhoA, Rac1, or Cdc42 activation using a small GTPase activation assay (G-LISA). Results were 
normalized to the microvesicle controls to determine fold-changes in activation. The mean and SD of 6 independent experiments are shown
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During previous investigations into the histone deacet-
ylase family of enzymes, we discovered that pharmaco-
logical blockade of HDAC6 with specific or pan-HDAC 
inhibitors significantly enhanced HIV infection [16]. This 
effect appeared due to the formation of stable acetylated 
microtubules that serve as conduits for HIV transport 
to the nucleus, enhancing the kinetics and efficiency of 
reserve transcription, nuclear import, and integration 
[16–19]. Overall these data suggest that protein modifica-
tions—independent of overall expression level—may play 
critical roles in HIV replication. In this study, we sought 
to better define the role for post-translational modifi-
cations during HIV replication by utilizing a focused 
small-molecule inhibitor library with known effects on 
these mechanisms. This study demonstrates that the 
use of a low-cost pharmacological library coupled with 
semi-automated flow cytometry is an effective method 
to identify novel biological mechanisms modulating HIV 
infection.
In order to maximize the relevance to in  vivo viral 
replication, experiments were performed using primary 
CD4+ T cells infected with reporter viruses harboring 
patient-derived HIV-1 envelope. None of the compounds 
tested were found to influence viral fusion; however, 
the fungal metabolite chaetocin inhibited β-lactamase-
mediated CCF2 dye cleavage in a fusion-independent 
manner, likely due to inhibition of the β-lactamase 
enzyme itself. In stark contrast, we observed 39 com-
pounds within the library that altered HIV infection with 
greater than ±0.5 log2 fold change in EGFP expression. 
Within this group, 23 were found to increase infection, 
including 17 separate HDAC inhibitors, greatly strength-
ening our previous findings that these enzymes impact 
viral replication [16]. Two additional compounds tar-
geted the BRD2/4 proteins, inhibitors of which are cur-
rently being investigated as reactivators of latent HIV 
proviruses for ‘shock and kill’ strategies to eliminate 
viral reservoirs [34–38]. Conversely, 15 compounds were 
found to decrease viral infection, encompassing multiple 
compounds targeting methylation, acetylation, and cell 
signaling pathways. Three of these compounds—chae-
tocin, tenovin-6, and UNC0638—markedly reduced cell 
viability, suggesting they were inhibiting HIV replication 
by killing cells. The remaining compounds in the study 
all demonstrated cell viabilities of at least 70% of the no-
drug control.
Although a variety of cellular pathways influencing HIV 
infection were identified in this screen, several overarch-
ing themes were apparent. Multiple compounds tested 
here targeted mechanisms involved in cellular tran-
scription, including UNC1215, GSK-J4, PFI-1, and (+)-
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Fig. 8 HIV signaling through CD4 and CCR5 alters the landscape of GTPase-regulating proteins. a Rho family GTPases are regulated by guanine 
dissociation inhibitors (GDIs), guanosine exchange factors (GEFs), and GTPase activating proteins (GAPs). GTPase-regulating proteins with ±0.5 log2 
fold changes in phosphopeptide expression levels following HIV-1 signaling via CD4 and CCR5 as compared to a microvesicle control are listed.  
b Log2 fold changes in intensity of phoshopeptides from GTPase-regulating proteins 1 min after exposing cells to inactivated HIV-1 viruses
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enzymes respectively, both of which have reported mech-
anisms regulating histone methylation and gene silencing 
[52, 53]. This observation strengthens a role for promoter 
methylation status in the context of productive versus 
latent viral gene expression. Investigating the relationship 
between these compounds and the degree of methylation 
on HIV-associated DNA may provide further insight into 
how manipulation of methylation patterns alters HIV 
infection.
Inhibition of the bromodomain proteins BRD2/BRD4 
by compounds PFI-1 and (+)-JQ1 were found to increase 
infection. BRD family members have become an impor-
tant focus of shock-and-kill eradication strategies as 
inhibition has been shown to reverse viral latency by 
improving Tat interactions at the HIV promoter and by 
enhancing transcription elongation [34, 35, 54]. Here, 
we observe that PFI-1 and (+)-JQ1 enhance HIV infec-
tion, likely by promoting LTR transcription and thereby 
disfavoring immediate viral silencing following infection 
of unstimulated primary CD4+ T cells. However, it will 
be important to determine if these compounds—like the 
HDAC inhibitors—have additional mechanisms enhanc-
ing infection that could complicate strategies to eradicate 
latent reservoirs.
The screen performed in this study also revealed an 
inhibitor of Rho GTPase signaling that decreased HIV 
infection. The Rho GTPase family members and associ-
ated proteins have well-established relationships with 
cytoskeletal dynamics including actin and microtubules 
organization. Recently, it has become increasingly clear 
that the cytoskeleton plays in important role in traffick-
ing the virus from the periphery to the nucleus, increas-
ing the efficiency and kinetics of infection. Building on 
this initial result, we tested additional inhibitors to the 
Rho family GTPase Cdc42 and the downstream Rho-
associated protein kinase (ROCK), both of which also 
significantly reduced infection. These results suggest that 
multiple members of the Rho signaling family are host 
dependency factors promoting optimal HIV-1 infection 
of CD4+ T cells. Using a complementary unbiased pro-
teomic approach to identify phosphorylation changes of 
host proteins following HIV engagement and signaling 
through CD4 and CCR5, we observed large-scale re-
structuring of Rho GTPase signaling pathways includ-
ing significant phosphorylation changes in more than 20 
Rho GTPase associated proteins including the guanosine 
dissociation inhibitors (GDIs), guanosine exchange fac-
tors (GEFs), and GTPase activating proteins (GAPs) that 
regulate the activity of GTPases. These results were con-
firmed with a biochemical small GTPase activation assay 
which confirmed prior results demonstrating that Rac1 is 
activated by HIV signaling [51] and revealed Cdc42 as be 
a novel HIV signaling-responsive GTPase.
Exactly how Rho GTPases promote HIV infection 
remains unclear. Rho family signaling has an extensive list 
of downstream effectors and has been shown to regulate 
processes including cytoskeletal dynamics, transcription, 
endosomal trafficking, cytokinesis, cell cycle, and cell 
adhesion. The role of Rho family GTPases in the modula-
tion of cellular actin networks is well appreciated. With 
respect to HIV infection, signaling mediated through 
ROCK results in phosphorylation of downstream LIM 
kinases and the actin regulator cofilin, previously impli-
cated in promoting HIV infection of target cells [46]. 
Specifically, the activation of cofilin by HIV-CXCR4 
interactions is thought to assist viral entry by disrupting 
the cortical actin barrier of CD4+ T cells and facilitating 
passage into the cytoplasm. Early post-entry viral events 
are also modulated by actin-interacting proteins such as 
syntenin-1, ERM, vinculin, WASP, WAVE-2, and Arp2/3, 
many of which are also directly regulated by Rho family 
proteins [55]. Furthermore, Rho activation triggers the 
accumulation of ERM family and vinculin proteins to the 
plasma membrane to facilitate their involvement in actin 
remodeling.
More recently, it has become clear Rho family 
GTPase proteins, including RhoA, Rac, and Cdc42, also 
play a central role in controlling the dynamic organi-
zation and stabilization of microtubules. For instance, 
RhoA activates the formin protein diaphanous homolog 
1 (DIA1, DIAPH1, mDia1), which in turn recruits end 
binding protein 1 (EB1) and adenomatous polypo-
sis coli (APC), leading to the stabilization of dynamic 
microtubules [47]. Intriguingly, a role for EB1 in sta-
bilizing microtubules during HIV infection has been 
reported, mediated by HIV-1 matrix protein interact-
ing with EB1-binding protein Kif4 to promote stable 
microtubule formation [18]. Our results here indicate 
that viral manipulation of microtubule networks may 
in fact originate considerably earlier; namely during 
engagement of the CD4 and CCR5 receptors. A role 
for the Cdc42 protein in microtubule stability has also 
been described, specifically in the reorientation of the 
microtubule organizing center (MTOC) and micro-
tubules towards the immune synapse in CD4+ T cells 
and dendritic cells [49, 50]. Finally, the Rho-associated 
protein kinase (ROCK) has also been implicated as 
a regulator of microtubule stability via phosphoryla-
tion of the tubulin polymerization-promoting pro-
tein (TPPP), which in turn interacts with HDAC6 to 
modulate tubulin acetylation status [48]. Despite these 
advances in our understanding of Rho GTPase regula-
tion of cytoskeletal dynamics and viral infection, the 
precise molecular mechanisms through which RhoA, 
Cdc42, and ROCK promote viral infection remain 
unclear and are currently under investigation.
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Conclusions
Collectively, this study has reinforced the importance 
of the cytoskeleton in optimal HIV-1 infection of host 
cells and implicated RhoA, Cdc42, and ROCK as host 
dependency factors for viral replication. Furthermore, 
we have demonstrated that viral engagement of CD4 
and CCR5 activates Rac1 and Cdc42 and results in 
large-scale phosphorylation changes to proteins in the 
GTPase signaling cascade, indicating the viral hijacking 
of the cytoskeleton may be initiated during the earliest 
stages of HIV attachment to a target cell. Importantly, 
dependence upon Rho family GTPase signaling for 
optimal infection of target cells is not unique to HIV-1 
infection: adenovirus [56], Kaposi’s sarcoma herpesvi-
rus [57, 58], and influenza A virus [59] infections also 
require intact Rho function, suggesting that manipu-
lation of Rho GTPase signaling pathways to promote 
cytoskeletal reorganization may be a common feature 
among many viral infections involving a nuclear stage of 
the viral life cycle.
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